Connect your AI

TG Therapeutics TGTX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

BridgeBio PharmaBBIO

$22.59M—

Immunovant, Inc.IMVT

$0-100%

Krystal Biotech, Inc.KRYS

$6.5M+345%

Arrowhead ResearchARWR

$46.83M—

LQD

Liquidia CorporationLQDA

$1.75M+38.6%

Rhythm Pharmaceuticals, Inc.RYTM

$0-100%

Other financials

Income statement

Revenue$204.9M+69.6%

Gross profit$171.4M+62.8%

Operating income$34.8M+304%

Net income$19.8M+291%

EPS (diluted)$0.12+300%

Balance sheet

Cash & equivalents$442.2M+235%

Total debt$753.6M+197%

Total equity$583.1M+146%

Total assets$1.5B+133%

Cash flow

Operating cash flow-$17.9M+37.7%

CapEx$51.0K+104%

Free cash flow-$17.9M+37.6%

Valuation

Market cap$8.15B-14.3%

Enterprise value$8.46B-11.1%

P/E17.6×-225×

P/S11.6×-13.0×

Profitability

Gross margin83.1%-4.4pp

Operating margin21.3%+5.9pp

Net margin66%+55.8pp

FCF margin-6,328.4%+4,773pp

Returns & leverage

Return on equity112.6%+92.9pp

Debt / equity1.3×+0.2×

Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is TG Therapeutics's stock issuance proceeds?: TG Therapeutics (TGTX) reported stock issuance proceeds of $763K in Q1 2026.
How has TG Therapeutics's stock issuance proceeds changed year-over-year?: TG Therapeutics's stock issuance proceeds increased by 3533.3% year-over-year, from $21K to $763K.
What is the long-term trend for TG Therapeutics's stock issuance proceeds?: Over 3 years (2021 to 2025), TG Therapeutics's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $2.22M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.